Kamada Ltd. (NASDAQ:KMDA) Declares $0.17 Annual Dividend

Key Points

• Kamada declared an annual dividend of $0.17 per share, payable September 17 to shareholders of record on August 27. The reported 219% yield appears unusually high and may reflect a data error.
• Kamada’s latest quarterly results exceeded expectations, with EPS of $0.16 versus the $0.11 consensus and revenue of $54.92 million versus estimates of $50.84 million. Its dividend payout ratio is reported at 46.2%, indicating coverage by earnings.
• KMDA shares recently traded at $7.76, within a 12-month range of $6.50 to $9.35, while institutional investors own approximately 20.38% of the company.

Kamada Ltd. (NASDAQ:KMDA - Get Free Report) announced an annual dividend on Monday, August 17th. Shareholders of record on Thursday, August 27th will be paid a dividend of 0.17 per share by the biotechnology company on Thursday, September 17th. This represents a yield of 219.0%. The ex-dividend date of this dividend is Thursday, August 27th.

Kamada has a dividend payout ratio of 46.2% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Kamada to earn $0.60 per share next year, which means the company should continue to be able to cover its $0.18 annual dividend with an expected future payout ratio of 30.0%.

Kamada Price Performance

Kamada stock traded up $0.18 during mid-day trading on Monday, reaching $7.76. 353,565 shares of the stock traded hands, compared to its average volume of 64,856. Kamada has a 12-month low of $6.50 and a 12-month high of $9.35. The business's 50-day moving average is $7.22 and its 200-day moving average is $7.96. The stock has a market capitalization of $446.28 million, a PE ratio of 20.42, a price-to-earnings-growth ratio of 0.67 and a beta of 0.86.

Kamada (NASDAQ:KMDA - Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.11 by $0.05. Kamada had a return on equity of 8.37% and a net margin of 11.60%.The business had revenue of $54.92 million during the quarter, compared to the consensus estimate of $50.84 million. Equities analysts anticipate that Kamada will post 0.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of KMDA. Barclays PLC boosted its holdings in shares of Kamada by 417.1% in the 4th quarter. Barclays PLC now owns 4,788 shares of the biotechnology company's stock worth $34,000 after purchasing an additional 3,862 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in Kamada during the 4th quarter valued at $66,000. XTX Topco Ltd bought a new stake in Kamada in the fourth quarter worth $103,000. SIH Partners LLLP purchased a new position in Kamada during the fourth quarter worth $134,000. Finally, Quadrature Capital Ltd increased its position in Kamada by 53.5% during the fourth quarter. Quadrature Capital Ltd now owns 21,889 shares of the biotechnology company's stock valued at $155,000 after acquiring an additional 7,627 shares during the last quarter. 20.38% of the stock is currently owned by institutional investors.

About Kamada

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source